This report's primary goals are to reinforce the value of antipsychotic monotherapy in the treatment of schizophrenia, particularly TRS, and to discourage the overuse of APP in cases of poor response, especially in the absence of a previous clozapine trial. This evidence concerns the gene APP and schizophrenia.